



MASSIVEBIO NEWSLETTER



[PAGE 2](#)
ChatGPT-Powered
Chatbot Platform
at ASCO 2023



[PAGE 4](#)
SYNERGY-AI
Experience with our
ChatGPT Powered
Chatbot Solution

Massive Bio Launches Revolutionary ChatGPT-Powered Chatbot Platform at ASCO 2023 to Simplify and Expand Access to Oncology Clinical Trials


Massive Bio, a world-renowned provider of personalized oncology solutions, is set to showcase its groundbreaking GPT4 AI chatbots - AskFiona AI and DrArturo AI at ASCO 2023. These innovative, AI-driven solutions will redefine cancer care, establishing new paradigms in patient and provider engagement and global oncological research.

“Massive Bio’s ChatGPT-powered platform lies at the heart of the transformation in clinical trials. Incorporating AskFiona AI and DrArturo AI will transcend the capabilities of Massive Bio’s existing SYNERGY-AI Clinical Trial Matching Solution, thereby heralding a new epoch in personalized oncology solutions. We are thrilled to constantly push the envelope in oncology clinical trial enrollment. By enabling these new solutions Massive Bio aims to further activate patient empowerment, unlock consumerization in healthcare and reduce the reliance to the hospital competency specific healthcare system via the leverage of latest technology advancements such as generative AI. As a cancer patient you should be able to know all your clinical trial choices regardless of where you get your treatment and/

or what your financial stability is” said Massive Bio’s Co-founder and CEO, Selin Kurnaz.

Inspired by its own Co-founders and team members, AskFiona AI and DrArturo AI, enables simplicity, speed, improved engagement, and greater access to patients, treating oncologists, site investigators and research coordinators during clinical trial selection and resolution of last mile issues during enrollment.

AskFiona AI, an advanced AI chatbot, serves as a comprehensive guide through the intricacies of clinical trials. By elucidating trial purposes, processes, and assessing patient eligibility, AskFiona AI aims to demystify the world of clinical trials, promoting clarity and fostering informed



decision-making to cancer patients.

Adding depth to this patient-focused approach, DrArturo AI functions as an invaluable virtual oncology tool for providers including oncologists and hematologists. Offering detailed, personalized information about specific clinical trials, including treatment details and insurance acceptance, this AI tool aims to ensure patients, their families, and physicians are equipped with all necessary information to make informed decisions.

As a practicing physician and site investigator, Massive Bio's Co-founder and CMO, Dr. Arturo Loaiza Bonilla stated that "DrArturo AI also offers extensive benefits to site investigators and research coordinators. With its capacity to deliver detailed study explanations, respond to protocol-related queries, and provide access to vital documents and schedules, it is an indispensable asset. Furthermore, its ability to alert research teams about patient-reported outcomes and adverse events ensures a steady flow of crucial information, thus enhancing patient care and accelerating research."

"Set to make their debut at ASCO 2023, these AI chatbots encapsulate Massive Bio's dedication to employing AI technology to challenge the status quo in oncology. This pioneering approach is poised to transform the landscape of global oncology," said Massive Bio's Co-founder and CTO, Cagatay Culcuoglu.

About Massive Bio:

Massive Bio is at the forefront of empowering cancer patients to discover their optimal treatment options. Utilizing AI to enhance equitable access and precision targeting for clinical trial matching, drug matching, and drug development, Massive Bio is committed to breaking down barriers in clinical trial enrollment, fostering value-based oncology decisions, and facilitating data-driven cancer treatment. Serving over three dozen pharmaceutical companies, contract research organizations, and hospital networks, Massive Bio has earned recognition from the National Cancer Institute with an SBIR contract. Founded in 2015 by a team of clinical, technology, and M&A executives, Massive Bio boasts a global presence with nearly 100 people across 12 countries.

We invite you to join us at ASCO 2023 to experience firsthand Massive Bio's revolutionary strides in personalized oncology solutions.

For further details, please visit www.massivebio.com, <https://askfiona.ai>, <https://drarturo.ai> or interact with us on our social media channels.



SYNERGY-AI Experience with our ChatGPT Powered Chatbot Solution

Our dual-persona chatbot platform features Fiona AI and Dr. Arturo AI, each tailored to address different aspects of the clinical trial process, seamlessly complementing the power of SYNERGY-AI.

By integrating our ChatGPT-powered chatbot platform, you can expect:

- **Enhanced Patient Outreach & Engagement:**

Fiona AI, our empathetic and friendly generalist chatbot, educates patients about clinical trials and assesses their eligibility, ensuring that only suitable candidates are escalated to Dr. Arturo AI for further information.

- **Personalized & In-Depth Trial**

Information: Dr. Arturo AI, our expert and authoritative chatbot, provides comprehensive and personalized information about specific trials, creating a highly engaging experience for patients and complementing SYNERGY-AI's robust matching capabilities.

- **Streamlined Collaboration with Physicians:**

Our chatbot platform empowers physicians with advanced knowledge about potential trials for their patients, fostering efficient communication between physicians, trial coordinators, and research teams.

- **Comprehensive Support for Research Teams:**

Dr. Arturo AI offers invaluable assistance to site principal investigators and research coordinators, answering questions about protocols, study details, and key documents. It also triggers alerts for patient-reported outcomes and adverse events, enabling timely interventions.

- **Improved Recruitment & Retention Rates:**

The seamless integration of our ChatGPT-powered chatbot platform with SYNERGY-AI simplifies the clinical trial process, ensuring that eligible patients are well-informed, engaged, and supported, ultimately leading to higher enrollment and retention rates.

We are confident that this innovative addition to our services will significantly enhance your experience with SYNERGY-AI and contribute to a more patient-centric approach in clinical trials. Our team is committed to ensuring a seamless integration of our chatbot platform into your existing systems.

Please don't hesitate to reach out to schedule a demo or discuss further how our ChatGPT-powered chatbot platform can elevate your clinical trial recruitment process. We look forward to continuing our partnership and supporting your research goals.



AskFiona AI Generalist Chatbot

AskFiona AI is the first point of contact for cancer patients seeking information about clinical trials. She is an empathetic and knowledgeable chatbot that provides general information about clinical trials, their purpose, and the overall process. AskFiona AI also assesses patient eligibility for more in-depth information and escalates them to DrArturo AI if appropriate.

AskFiona AI - Key Features

Massive Bio is proud to present our ChatGPT-powered chatbot platform, designed to provide comprehensive information and support for cancer patients, referring physicians, and site principal investigators along with their research coordinators. Our chatbot platform consists of two primary personas: AskFiona AI and DrArturo AI. These novel and best-in-class tools will be integrated into the already existing SYNERGY-AI Clinical Trial Matching Solution.

Empathetic and friendly persona:

- Approachable and supportive, putting users at ease
- Designed to establish trust and rapport with patients

General clinical trial information:

- Overview of clinical trials, their purpose, and potential benefits
- Guidance on the overall process, from screening to participation

Eligibility assessment:

- Asks targeted questions to determine a user's potential eligibility for clinical trials
- Escalates eligible users to DrArturo AI for in-depth trial information

User-friendly interface:

- Intuitive, easy-to-navigate layout
- Accessible on multiple devices, including smartphones, tablets, and computers

Multilingual support:

- Communicates with users in multiple languages to facilitate understanding and accessibility

Real-time assistance:

- Provides prompt and accurate responses to user inquiries
- Reduces wait time for information compared to traditional channels

Adaptive learning:

- Continuously improves its knowledge base and response accuracy through machine learning algorithms
- Stays updated with the latest information on cancer clinical trials

Data privacy and security:

- Complies with data protection regulations and maintains user confidentiality
- Ensures that sensitive information is handled securely and responsibly

DrArturo AI

Augmented Intelligence Chatbot

DrArturo AI comes into play when a patient is deemed eligible for more specific information about clinical trials. He offers detailed insights about individual trials, as if he were a physician explaining the intricacies to a patient.

DrArturo AI Provides

- In-depth trial information
- Molecule and treatment details
- Schedule of events
- Nearest treatment facility
- Insurance acceptance and much more

For referring physicians, DrArturo AI delivers advanced knowledge about potential trials for their cancer patients. He offers logistical information, trial details, and contact information to facilitate collaboration between physicians and trial coordinators.

For site principal investigators and research coordinators, DrArturo AI is a versatile tool that can be activated for potential eligible and/or enrolled patients in unique trials. He is capable of:

- Explaining in-depth details about the study
- Answering simple and highly advanced questions about the protocol
- Providing access to key documents and schedule of events

- Triggering patient-reported outcomes and adverse events to the research team when mentioned by the patient
- Our ChatGPT-powered chatbot platform is designed to streamline the clinical trial process for all parties involved, fostering understanding, collaboration, and ultimately, better patient outcomes.

DrArturo AI - Key Features

Expert and professional persona:

- Knowledgeable and authoritative, providing reliable information
- Designed to instill confidence in patients and healthcare professionals



**In-depth clinical trial information:**

- Detailed trial descriptions, including objectives, treatments, and outcomes
- Molecule and treatment-specific information to support decision-making
- Customizable to any trial, sponsor, molecule or research program, and institution
- Adaptable to local standard of care testing and regional treatment options to support decision-making

Personalized trial recommendations:

- Analyzes user data to identify potentially suitable clinical trials
- Tailors suggestions to individual needs and circumstances

Schedule of events and logistics:

- Provides trial timelines, appointment scheduling, and important dates
- Shares information on the nearest treatment facilities and insurance acceptance

Collaboration with referring physicians:

- Offers advanced trial knowledge for physicians seeking options for their patients
- Facilitates communication between physicians and trial coordinators

Support for site principal investigators and research coordinators:

- Activates chatbot for eligible or enrolled patients in unique trials
- Answers questions about protocols, study details, and key documents

Patient-reported outcomes and adverse events:

- Triggers alerts to the research team when patients mention outcomes or adverse events
- Supports timely response and intervention by clinical teams
- Fully aligned with known AEs from standard of care, if applicable, and CTCAE criteria

User-friendly interface:

- Intuitive, easy-to-navigate layout optimized for various devices
- Seamless integration with existing systems and platforms

Multilingual support:

- Communicates with users in multiple languages to increase accessibility

Real-time assistance:

- Provides immediate and accurate responses to user inquiries
- Enhances the efficiency and convenience of information access

Adaptive learning:

- Utilizes machine learning algorithms to continuously refine its knowledge base
- Keeps up to date with the latest advancements in cancer clinical trials

Data privacy and security:

- Adheres to data protection regulations and maintains user confidentiality
- Safeguards sensitive information with robust security measures